Loading...
Loading...
OCUP| Name | Value |
|---|---|
| Revenues | 1,691.0K |
| Cost of Revenue | 3.0K |
| Gross Profit | 1,688.0K |
| Operating Expense | 7,117.0K |
| Operating I/L | -5,429.0K |
| Other Income/Expense | 632.0K |
| Interest Income | 0.0K |
| Pretax | -4,797.0K |
| Income Tax Expense | -2.0K |
| Net Income/Loss | -4,795.0K |
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company specializing in developing and commercializing therapies for refractive and retinal eye disorders. Its lead product candidate, Nyxol eye drops, is a preservative-free formulation in Phase III clinical trial for dim light or night vision disturbances and Phase 2b clinical trial for pharmacologically induced mydriasis. The company also focuses on developing APX3330, an oral tablet targeting pathways relevant to retinal and choroidal vascular diseases, and second-generation preclinical product candidates and analogs of APX3330.
